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Correctional environments are increasingly being
recognized as settings in which society's infec-
tious diseases are concentrated.1 Most studies on
infectious disease in correctional
facilities address prisons, but
infectious diseases are even
more prevalent in jails. In particu-
lar, sexually transmitted diseases
(STDs) may be more common in
jail settings than in prisons, as
inmates who are sentenced and
sent to prison will typically have
been in jail long enough to have
been diagnosed and treated for
some STDs.  
Although there have been some notable success-
es in identifying these diseases, rapid turnover
and frequent movement of inmates makes jails dif-
ficult settings in which to quantify the prevalence
of various diseases. There is also a tendency to
deal only with urgent medical conditions in jails,
with mental illness, drug withdrawal, and tubercu-
losis commanding the most attention. As a result,
other chronic illnesses and STDs may not be
addressed routinely in the jail setting.
This discussion will focus on the epidemiology,
diagnosis and treatment of four of the most com-
mon STDs found in the jail setting: syphilis, gon-
orrhea, chlamydia, and genital herpes. The con-
nection between genital-ulcerative STDs and the
acquisition and transmission of HIV will also be
discussed. The viral hepatitides, which may be
sexually transmitted, will not be included in this
discussion.
EPIDEMIOLOGY
Syphilis
Health officials in the U.S. were alarmed to find
that after declining for many years, syphilis rates
began to increase in early 2000.2 The 2001 rate
was 2.2 cases per 100,000, up from the rate of 2.1
cases per 100,000 in 2000.3 (See Table 1.) There
is a large geographical variation in the rates of pri-
mary and secondary syphilis, with the highest
rates reported in the South. The reported rates of
syphilis are higher in correctional environments
than in the non-incarcerated population. In 1990,
an outbreak of syphilis in New York City led to
intake syphilis screening and control initiatives in
NYC jails. In one jail, syphilis was found in 3.3% of
new inmates who were screened.4
Much of the recent increase in
syphilis rates seen in the general
population has been among men
who have sex with men (MSM),
although higher rates are also
reported for women (compared to
men) and African-Americans (com-
pared to non-African Americans).2
Gonorrhea and Chlamydia
After decreasing for several years,
the rates of gonorrhea and chlamy-
dia in the U.S. have increased sharply.5 In addition
to a 9% increase in the number of cases from
1997-1999, recent studies have reported a
change in antibiotic susceptibility for gonorrhea,
with susceptibility to azithromycin and fluoro-
quinolones decreasing in Hawaii and California in
2001.6,7
The overall reported rates of gonorrhea and
chlamydia in the U.S. in 2000 were 131.6/100,000
and 257.5/100,000, respectively. There is a high
prevalence of Neisseria gonorrhea and Chlamydia
trachomatis in jails and juvenile detention centers,
especially among women, as documented in a
screening of women entering facilities in Chicago,
IL, Birmingham, AL, and San Francisco, CA. The
rates ranged from five to nine percent for gonor-
rhea, and twice that for chlamydia, with a range of
11% to 17%. One to two percent of women in this
sample were found to be infected with both dis-
eases.8
The reported rates of gonorrhea and chlamydia in
women are dependent upon how aggressively
screening is performed. Many women with these
infections are asymptomatic, and small amounts
of vaginal discharge may go unnoticed. Left
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Managing Sexually Transmitted Diseases in Jails
STDs are not 
routinely
addressed in 
jails, but 
should be.
untreated, infection can lead to pelvic inflam-
matory disease, salpingoophoritis, tubo-ovar-
ian pregnancy and sterility. The greatest risk
for acquiring gonorrhea and chlamydia is in
younger, sexually active women, as their less
mature cervices have been found to be more
vulnerable to infection. 
Men with gonorrhea tend to present with
symptoms of pain, dysuria, tenesmus, and
anal and/or penile discharge, with signs and
symptoms dependent upon the site of infec-
tion. Chlamydia infection may present with
scant urethral discharge or florid symptoms.
The rate of asymptomatic disease is unknown
for both of these infections.9
Because most facilities do not perform intake
screening for gonorrhea or chlamydia on
asymptomatic men, the prevalence of dis-
ease is difficult to estimate.10 In the year
2000, most facilities reporting chlamydia in
males were juvenile prisons. Their rates
ranged from 0.8% in Oregon to 13% in Texas.
Rates from the few jail facilities that reported
ranged from 5.4% in Northern California to
21% in Northern Florida.11
Herpes
Genital herpes is a lifelong infection charac-
terized by recurrent outbreaks of HSV
serotypes 1 and/or 2. HSV-2, the most com-
mon cause of recurrent episodes of genital
herpes simplex, is notoriously under-diag
nosed. It is believed that most people with
HSV do not know they have it and since it can
be spread with asymptomatic shedding of
virus, it is particularly easy to transmit.
Estimates are that 50 million people in the
U.S. have genital HSV infection.12
Besides the discomfort of repeated genital
herpes outbreaks and the transmission of
HSV-2 during symptomatic and asympto-
matic periods, there have been concerns that
recurrent HSV may play a role in HIV acquisi-
tion and transmission. In a study by Schacker
et al., 12 men with HIV disease were studied.
HIV-1 was isolated from 25 of 26 HSV-2
lesions during recurrence in all 12 of the men
for 67% of the days when genital lesions were
noted. None of the 12 were on antiviral thera-
py for HSV during the study. Only three of the
12 were on therapy for HIV disease.13 The
increased risk of HIV acquisition is estimated
to be anywhere from two to four times higher
when HSV infection is present.14 A prelimi-
nary study from Africa suggested that sup-
pressive therapy with acyclovir for patients
with HSV-2 could be an effective method for
decreasing the risk of HIV acquisition.15
DIFFICULTIES DIAGNOSING AND
TREATING STDS IN JAILS
When discussing diagnosis or treatment for
any illness within corrections, it is important to
be aware of the differences between jails and
prisons.
Recognition of these differences does not
suggest that diagnosis and management of
STDs in either of these two environments is
simple, but highlights the challenges. In pris-
ons, one of the priorities is preventing the
introduction of STDs into the inmate popula-
tion; there may be less concern and urgency
regarding transmission to the outside com-
munity. In jails, the priorities include diagnosis
and treatment within the jail, with great con-
cern for decreasing transmission to the com-
munity and prison facilities. 
Many have looked at the jail environment as
key to controlling STDs, noting high rates of
untreated sexually transmitted diseases with-
in minority communities with high incarcera-
tion rates.16 A similar argument has been
made for collaboration between jails, prisons,
and departments of health to diagnosis, track,
and report STD trends in corrections.17Due to
the high rates of STDs within jails, and the
subsequent impact on outside communities,
s veral strategies have evolved to address
the issues paramount in jail environments. 
In 1997, an assessment of the STD services
within city and county jails indicated that most
facilities treated for STDs based on symp-
toms or by arrestee request and did not rou-
tinely screen asymptomatic inmates. Less
than half of the jails assessed had a policy of
ffering routine screening, and even in those
facilities with routine screening, fewer than
half of the inmates were tested for syphilis,
gonorrhea, or chlamydia. In those facilities
using symptomatic screening for STDs, less
than eight percent of women and less than
three percent of men were tested. This study
also documented a common feature of jails:
approximately half of arrestees were released
within 48 hours and most facilities received
the inmates' test results more than 48 hours
after admission.18
DIAGNOSIS OF STDS
The diagnosis of STDs requires a high index
of suspicion, a thorough non-judgmental sex-
ual history, and a careful genital exam. All
inmates should be screened for STDs and the
type of screening in a facility should be based
on prevalence as measured by the population
served. 
Due to the absence of signs and symptoms in
many of those who are infected, it may be dif-
ficult to diagnose syphilis unless the medical
provider happens upon a chancre of primary
syphilis or is convinced a disseminated skin
rash is secondary syphilis. Otherwise, syphilis
i  most often diagnosed by serologic testing
using the non-treponemal Rapid Plasma
Reagin (RPR) test or the Venereal Disease
Research Laboratory (VDRL) test.
Confirmatory specific treponemal tests
include the fluorescent treponemal antibody
absorbed (FTA-ABS) or MHA-TP. Most labo-
ratories will automatically confirm the positive
2
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State
Pennsylvania
Texas
Tennessee
Alabama
Louisiana
California
Non-incarcerated
Population
0.8
2.3
5.8
5.1
3.9
1.6
Incarcerated 
Men
3.0
5.1
0.3
3.4
3.4
2.8
Incarcerated
Women
10.0
10.5
21.2
9.3
7.1
4.4
TABLE 1: Rates of syphilis, selected states 2001, /100,000 population
Adapted from the Sexually Transmitted Disease Surveillance 2001 Supplement, Syphilis
Surveillance Report (CDC)
TABLE 2: Differences Between Jails and Prisons
Length of stay
Turnover
Population size
Communication with
local DOH*
Screening priorities
Age
Staffing
Jails
Brief; 24 hours to < one year
Rapid
Usually small
Moderate to extensive
Trauma, drug withdrawal,
suicide risk, STDs, TB
Younger
Less stable
Prisons
Usually > one year
Less rapid
Usually large
Low to moderate 
Chronic illnesses (e.g. hyper-
tension, diabetes, lung dis-
ease), TB
Older
More stable
Excerpted from Intake and Evaluation in Prisons and Jails, Clinical Practice in Correctional Medicine,
Michael Puisis, D.O. Mosby Incorporated 1998
*Ninth National Survey of HIV/AIDS, Sexually Transmitted Diseases, and Tuberculosis in Correctional
Facilities
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Dear Correctional Colleagues:
This month's issue focuses on sexually transmitted diseases (STDs) in jails. STD control is
an issue in its own right as well as a measure to prevent the spread of HIV. 
Correctional health care professionals can provide an effective service for society in hel-
ing control STDs. People who have been convicted of a crime have higher rates of medical
conditions that similarly involve risk taking, including STDs.  A few years ago it was report-
ed that 24% of Chicago's new syphilis cases were diagnosed at the Cook County Jail.
Similarly, 13% of Florida's syphilis cases were identified by correctional facilities. Working
together with public health departments, we can design programs that can be among the
most effective ways to diagnose STDs in our communities. As those cases are reported and
as partners/contacts are contacted by public health departments and treated, control of
STDs can be greatly advanced. 
We should be screening all our incoming inmates to diagnose and treat patients with STDs.
Screening should be tailored to the population being served. Not all systems need to do lab
tests for all diseases, but we don't know that until we look. Although our systems try to min-
imize sexual activity within our facilities, it does occur. Assuring the absence of STDs at
least prevents disease transmission. Since it has been shown that the presence of STDs
facilitates HIV transmission, control of STDs is also an HIV preventive measure.
STD control in corrections must involve close collaboration with public health departments.
This is an area that state and local health departments have specialized in for decades.
They have staff trained to interview patients with STDs and to locate their sexual partners.
Their staff, clearly identified as health department officials, can sometimes get histories that
correctional staff cannot (since inmates may not believe that the information they tell us
won't be used against them). This collaboration is a win-win for society. If you don't already
know your health department colleagues, get to know them now!
After reading this issue, you will have a better understanding of the epidemiology, diagno-
sis, and treatment of four STDs commonly found in jail settings: syphilis, gonorrhea, chlamy-
dia and herpes. 
Dr. Lester Wright
New York State Department of Corrections
Letter from the Editor
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4non-treponemal test results with specific tre-
ponemal results. The use of one serologic
test without confirmation is insufficient for
diagnosis because false-positive non-tre-
ponemal results may be secondary to other
medical conditions.
The rapid RPR test is used to qualitatively
diagnosis syphilis. In high-prevalence set-
tings, in cases where other signs/symptoms
of syphilis exist, and when history of treat-
ment is non-existent or unreliable, positive
results can be used to justify empiric treat-
ment while awaiting quantitative results and
confirmatory treponemal tests. This is espe-
cially useful in the jail setting where patients
may not be available in 48 hours when most
test results return. 
The results of non-treponemal tests correlate
with disease activity and will usually revert to
negative following successful treatment,
though they may remain positive at low titer in
some individuals. This condition is referred to
as "serofast."
Treponemal antibody tests usually remain
positive for years, and sometimes for the life-
time of the patient, regardless of treatment or
disease activity. Fifteen to 25 percent of peo-
ple may revert to negative two to three years
after successful treatment. 
Previously, gonorrhea and chlamydia
required invasive examinations for samples
and either microscopic examination of fluid to
detect intracellular gram-negative diplococci
for GC, or culture to detect both. Currently,
nucleic amplification tests can be used on
fluid samples, including urine, and sensitively
diagnose both these infections. 
Primary genital herpes simplex infections
often present with significant signs and symp-
toms of pain at the vesicle, pustule, or ulcer
sites, slight fever, and inguinal lym-
phadenopathy dependent upon the extent of
lesions. Recurrences are often less sympto-
matic, may present with a prodrome of itching
or burning or may go completely unnoticed.
History and visual signs usually make a clini-
cal diagnosis fairly straightforward, but viral
culture can help identify which form of HSV
the patient has, and this has prognostic sig-
nificance. Generally HSV-1 recurs with less
frequency than HSV-2.
TREATMENT
The success of treatment for STDs depends
upon an accurate diagnosis, the correct
antibiotic or antiviral therapy, and the proper
duration of treatment. Multiple guidelines doc-
umenting treatment choices are available; the
most user-friendly version is the Sexually
Transmitted Diseases Treatment Guidelines
published by the CDC, which are regularly
updated.
Education on the prevention of acquisition
and spread of STDs should be included with
any treatment recommendations. The CDC's
Prevention Advisory Committee has recom-
mended integration of STD and HIV pro-
grams, but current increases in STDs among
HIV-positive men who have sex with men
(MSM) highlights the overall failure of this
integration to date.19
CONCLUSION
Although this article addressed only four of
the many STDs, these four are significantly
prevalent within jails. There has been a resur-
gence in sexually transmitted diseases in
recent years and the correctional environment
is not exempt from this increase in case rates.
If anything, the jail environment is a startling
example of this resurgence. Diagnosis and
treatment within corrections, especially jails,
can have an impact on the prevalence of dis-
ase within jails and the communities they
serve. 
Obviously, most arrestees do not enter the
correctional environment for the sole purpose
of receiving health care. However, it is incum-
bent upon medical providers to do what they
can to approach patients and determine and
address their health needs, even with limited
resources and time. This is true even for
patients who are not aware of these health
needs. This approach is important regarding
STDs, as patients may have minimal or no
symptoms, leading to transmission of these
infections inside and outside the jail setting. 
*DISCLOSURES: Consultant: Bristol-Myers
Squibb, Gilead, Abbott Laboratories.
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TABLE 3: Ways to Increase Diagnosis and Treatment of STDs in Jail Inmates
Method
Routinely test for com-
mon STDs prevalent
within community at
large. Use of rapid
RPR, and urine ligase
tests for GC and
chlamydia.
Surrogate markers for
evidence of STDs, e.g.
urine dipstick looking
for leukocyte esterase.
Close collaboration
with local departments
of health.
Advantage
1. Will likely increase numbers of
arrestees diagnosed with STDs.
2. Urine ligase tests for GC and
chlamydia increase acceptance
and accuracy of testing.
3. Earlier diagnosis and/or suspi-
cion may lead to increased treat-
ment success, decreased trans-
mission within corrections and
positively impact at-large com-
munity.
4. Increased surveillance 
capability for local Department 
of Health.
1. Relatively inexpensive with
immediate results.
2. Useful in high prevalence
areas with rapid turnovers of
arrestees who may not be avail-
able for follow-up evaluation.
3. Often already used to diag-
nose sequelae of other chronic
conditions.
1. Useful for continuity of care
into and out of corrections, con-
tact tracing, and partner notifica-
tion.
2. Cost savings when previous
treatment completion confirmed.
3. Field-delivered therapy will
increase completion of treatment
and decrease community spread
of disease.
4. Useful for training in recogni-
tion of and treatment for STDs.
Disadvantage
1. Increased laboratory and
pharmaceutical cost for diag-
nosis and treatment.
2. Increased diagnosis may
not lead to increased treat-
ment due to rapid turnover in
jails.
3. May depend upon aware-
ness of STD prevalence in
outside communities.
1. Due to poor sample quali-
ty, may lead to over-treat-
ment. Subject to interpreta-
tion.
2. Does not offer accurate
diagnosis for treatment or
surveillance purposes.
1. There may be a significant
delay in data entry, which
may alter certainty of treat-
ment completion. This may
lead to either over-treatment
or under-treatment.
2. Use of aliases may make
documentation difficult.
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Disease
Primary and 
secondary syphilis 
Early latent syphilis
(<one year duration)
Latent syphilis 
(>one year duration
or unknown)
Neurosyphilis
Syphilis in
Pregnancy
Neisseria gonorrhea
Chlamydia 
trachomatis
Chlamydia in preg-
nancy
Herpes simplex, first
clinical episode
Genital herpes,
recurrence
Recommendation
Benzathine penicillin 2.4 
million units IM in a single
injection
Benzathine penicillin 2.4 
million units IM for three doses
at one-week intervals 
Aqueous crystalline penicillin
G 18-24 million units per day,
administered as 3-4 million
units IV every four hours or
continuous infusion, for 10-14
days
Penicillin regimen appropriate
for stage of syphilis
1. Ceftriaxone 125 mg IM in a
single dose, or 
2. Ciprofloxacin 500 mg orally
in a single dose, or
3. Ofloxacin 400 mg orally in a
single dose, or
4. Levofloxacin 250 mg orally
in a single dose(quinolones not
recommended in infection
acquired in CA or HI)
1. Azithromycin 1g orally in a
single dose, or 
2. Doxycycline 100 mg orally
twice daily for seven days
1. Erythromycin base 500 mg
orally four times daily for
seven days, or
2. Amoxicillin 500 mg orally
three times daily for seven
days
1. Acyclovir 400 mg three
times daily for seven to 10
days, or
2. Acyclovir 200 mg orally five
times daily for seven to 10
days, or 
3. Famciclovir 250 mg orally
three times daily for seven to
10 days, or
4. Valacyclovir 1 g orally twice
daily for seven to 10 days
Episodic therapy: 
1. Above regimens for five
days, or 
2. Valacyclovir 500 mg for
three to five days
Alternative regimen
1. Doxycycline 100 mg po bid for 14
days, or
2. Tetracycline 500 mg po qid for 14
days
1. Doxycycline 100 mg po bid for 28
days, or
2. Tetracycline 500 mg po qid for 28
days
Procaine penicillin 2.4 million units
IM once daily plus Probenicid 500
mg orally four times a day, both for
10-14 days
Penicillin allergic pregnant patients
should be desensitized to penicillin
Plus treat for chlamydial infection 
if it has not been ruled out
1. Erythomycin base 500 mg orally
four times daily for seven days, or
2. Erythromycin ethylsuccinate 800
mg orally four times daily for seven
days, or
3. Ofloxocin 300 mg orally twice
daily for seven days, or
4. Levofloxacin 500 mg orally daily
for seven days
1. Erythomycin base 500 mg orally
four times daily for 14 days, or
2. Erythromycin ethylsuccinate 800
mg orally four times daily for seven
days, or
3. Erythromycin ethysuccinate 400
mg orally four time daily for 14 days,
or
4. Azithromycin 1g orally in a single
dose
Suppressive therapy:
1. Acyclovir 400 mg orally twice
daily, or
2. Famciclovir 250 mg orally twice
daily, or
3. Valacyclovir 500 mg orally once
daily, or
4. Valacyclovir 1 g orally once daily
TABLE 4: Treatment RecommendationsManaging STDs...
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6Discussion: GUD is often difficult to diagnose due to the variability in
clinical presentation. A correct and rapid diagnosis is important, how-
ever, as an inaccurate or delayed diagnosis leads to a delay in treat-
ment and therefore increases the likelihood that the inmate may
infect others through sexual encounters. Incarcerated persons enter-
ing correctional facilities are at high risk for having sexually transmit-
ted diseases (STDs) because of the high prevalence of risky sexual
behaviors and limited access to health care for routine STD screen-
ing.1 In one study of adults screened for STDs on entering one of 23
jails, the prevalence of syphilis reactivity was found to be as high as
7.8% for men and 23.8% for women.2
Evaluation of Genital Ulcer Disease
The work-up for GUD begins by considering its infectious and non-
infectious causes. Infectious causes of GUD include genital herpes,
primary syphilis, chancroid, granuloma inguinale, and lymphogranulo-
ma venereum. Genital herpes, caused by herpes simplex virus (HSV)
1 and 2, is the most prevalent cause of GUD in North America, fol-
lowed by primary syphilis (Treponema pallidum), and chancroid
(Haemophilus ducreyi).3 Granuloma inguinale (donovanosis), caused
by the bacterium Calymmatobacterium granulomatis, nd lymphogran-
uloma venereum (LGV), caused by Chlamydia trachomatisserovars
L1-3, are rare causes of GUD in the United States. Donovanosis is
endemic in certain tropical and developing areas, such as India; Papua
New Guinea; Central Australia; and Southern Africa.4 A discussion of
non-infectious causes of GUD is beyond the scope of this article, but
should be considered if the work-up for infectious causes is negative.
Diagnostic Considerations
It is sometimes possible to make a diagnosis of GUD based on clinical
criteria (medical history and physical examination) alone. However, the
accuracy of a diagnosis based solely on history and a physical is high-
ly variable, ranging from 22% to 80%.5 A thorough evaluation of all
patients who have genital ulcers should include a serologic test for
syphilis. It should also include a diagnostic evaluation for genital her-
pes by isolation in cell culture or direct fluorescent antibody (DFA) test-
ing for type-specific and nonspecific antibodies to HSV. In settings
where chancroid is prevalent, a culture for Haemophilus ducreyion
special culture medium may be performed. However, H. ducreyiculture
lacks sensitivity and the special culture medium is not widely available.
A presumptive diagnosis of chancroid can be made if 1) the patient has
one or more painful genital ulcers, 2) the patient is not RPR-reactive
based on a test performed at least seven days after onset of ulcers, 3)
the clinical presentation (appearance of genital ulcers and presence of
tender, suppurative regional lymphadenopathy) is typical for chancroid,
and 4) evaluation for HSV is negative. A diagnosis of syphilis can be
made from a positive nontreponemal test (Venereal Disease Research
Laboratory [VDRL]) or reactive RPR, confirmed by a treponemal test
(serum fluorescent treponemal antibody absorption (FTA-ABS) and
MHA-TP. A biopsy of the ulcers may be helpful in identifying the etio-
logic pathogen if response to initial therapy is poor.4 Finally, the asso-
ciation between GUD and risk for HIV has been shown consistently.12
HIV antibody testing should be included in the evaluation of all patients
presenting with GUD. 
Syphilis
The risk for acquisition of syphilis from an infected sexual partner has
been estimated at about 30%.6 Transmission via blood products is the-
oretically possible since syphilitic organisms may survive for up to five
days in refrigerated blood. However, the risk of transmission from a
blood transfusion is negligible due to uniform serologic testing of all
bl od donors and a shift from transfusion of fresh blood to transfusion
of refrigerated blood components.7 Needle sharing does not appear to
play a role in syphilis transmission.8
Natural History 
Patients may present for evaluation and treatment of signs/symptoms
related to the different stages of syphilis infection: primary, secondary,
latent, or tertiary. Primary syphilis is heralded by the appearance of a
chancre, usually a single, painless, indurated ulcer with a clean base,
and regional lymphadenopathy, on average three weeks after expo-
sure. The physical appearance of these lesions may vary considerably,
which makes clinical diagnosis based on visual examination unreli-
able.9 In men, lesions most commonly appear on the penis, specifical-
ly the coronal sulcus and glans. Anorectal chancres are common in
men who have sex with men. In women, the lesions usually present on
the labia majora, labia minora, fourchette, and perineum. 
The onset of secondary syphilis typically occurs within a few weeks of
primary chancre resolution. Manifestations are protean, ranging from a
rash to central nervous system (CNS) involvement. The cutaneous
lesions of secondary syphilis may easily be mistaken for other derma-
tologic conditions. Rashes can range from macular to maculopapular,
follicular, and occasionally pustular. A rash due to secondary syphilis
tends to be universally distributed and nonpruritic, commonly involving
the  palms and soles. Some patients may experience various degrees
of pruritus.10 In untreated patients, the lesions resolve over several
weeks and may heal with scarring or abnormal pigmentation. Other
clinical manifestations of secondary syphilis include low-grade fever,
malaise, lymphadenopathy (painless and most commonly involving the
suboccipital, cervical, posterior auricular, and epitrochlear nodes),
mucosal lesions (mucous patch involving the tongue, buccal mucosa,
and lips), condyloma lata, alopecia ("moth-eaten appearance"), menin-
gitis, ocular involvement and headaches. 
L tent syphilis is defined as the period from the disappearance of the
Case presentation by Stephen Tabet*, M.D., M.P.H., Assistant Professor of Medicine, University of Washington, and Director, Northwest Correctional
Medicine Education Program. Case discussion by Kinji Hawthorne*, M.D., Senior Infectious Diseases Fellow, University of Washington School of
Medicine. A collaboration with the Northwest AIDS Education and Training Center, with Stephen Tabet, M.D., and Kate Willner, trainer.
Ask the Expert
Case Study: Newly-admitted Patient with a Penile Lesion
(Continued on page 7)
Case: A 27-year-old male presents to the prison infirmary with penile pain. He reports having had the pain for the past three days, ever since
accidentally catching part of the skin of his penis in his pants zipper. The patient reports previous good health. He is mildly developmentally
delayed and has bipolar affective disorder for which he takes Depakote. The patient arrived at this facility one week ago and is newly incar-
cerated. He denies any sexual activity since he arrived. He reports being in a monogamous relationship with a woman for the past year. He
denies ever having sex with men. The patient is examined by the infirmary nurse and found to have a 1.0 cm x 0.5 cm single oval lesion on
the shaft of the penis and pronounced bilateral inguinal adenopathy. The on-call doctor is consulted; he prescribes a topical antibiotic oint-
ment. Three weeks later, the patient is seen in follow-up. While the penile lesion has resolved, he now has a macular/pustular rash on his
chest. A rapid plasma reagin (RPR) test is ordered. It is reactive at 1:128. The diagnosis of syphilis is confirmed by microhemagglutination
assay for Treponema pallidum(MHA-TP).
What is the patient's diagnosis at initial presentation?The patient more than likely has genital ulcer disease (GUD) due to genital herpes,
primary syphilis, or chancroid.
What is the patient's diagnosis on second presentation?His diagnosis is secondary syphilis.
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7secondary manifestations until either a therapeutic cure occurs or ter-
tiary manifestations develop.8 Latent syphilis is arbitrarily divided into
early phase (from the onset of infection to less than one year) and late
phase (more than one year after infection). The length of time for latent
syphilis varies from person to person.  
Tertiary syphilis may involve the skin, bones, CNS, cardiovascular sys-
tem, and great vessels. The five major categories of CNS syphilis
include 1) asymptomatic (presence of cerebral spinal fluid [CSF]
abnormalities in the absence of neurologic symptoms or signs), 2)
meningeal, 3) meningovascular (diffuse encephalitic presentation with
superimposed focal signs), 4) parenchymatous (rare since modern
antibiotic era; may present as paresis or tabes dorsalis), and 5) gum-
matous (rare). In patients who are co-infected with HIV the natural his-
tory of syphilis may be altered significantly, resulting in an overlap of
syphilitic stages, making delineation of stages on clinical grounds
exceedingly difficult.11 This is rare in non-HIV infected persons.
Treatment and Follow-up
For primary and secondary syphilis, parenteral benzathine penicillin G
has been the treatment of choice for 50 years and is key for achieving
clinical resolution, preventing sexual transmission and preventing late
sequelae. The recommended dose is 2.4 million units intramuscularly,
in a single dose. In non-pregnant patients who are penicillin-allergic
and who have primary or secondary syphilis, either doxycycline 100
mg orally twice daily for 14 days or tetracycline 500 mg four times daily
for 14 days are the accepted alternative regimens. Pregnant patients
or patients with penicillin allergy whose adherence to therapy or follow-
up cannot be ensured should be desensitized and treated with benza-
thine penicillin. Follow-up should consist of a clinical reexamination
and serological testing at six months and 12 months following treat-
ment. HIV co-infected patients should be evaluated at three-month
intervals instead of six-month intervals. Nontreponemal test antibody
titers (quantitative RPR or VDRL) are better correlates of disease activ-
ity than are treponemal tests. 
Failure of nontreponemal test titers to decline fourfold within six
months after therapy for primary or secondary syphilis, or signs/symp-
toms that persist or recur are indicative of probable treatment failure.
Patients who fail to respond should be reevaluated for HIV infection.
Other reasons for a lack of therapeutic response that should be con-
sidered include re-infection with T. pallidumand unrecognized CNS
infection; however, re-infection usually cannot be reliably distinguished
from treatment failure. To rule out possible CNS infection, CSF analy-
sis is generally recommended. Patients who fail to respond should be
re-treated with benzathine penicillin G 2.4 million units intramuscularly
given weekly on three doses if CSF analysis for CNS infection is neg-
ative. In rare situations where serologic titers do not decline despite a
negative CSF examination and a repeated course of therapy, no addi-
tional treatment or repeat CSF examinations are warranted.
For early latent syphilis, benzathine penicillin G 2.4 million units intra-
muscularly in a single dose is recommended. For late latent syphilis or
latent syphilis of unknown duration, benzathine penicillin G 2.4 million
units intramuscularly weekly for three weeks is recommended. For
non-pregnant, penicillin-allergic patients presenting with early latent
syphilis, either doxycycline (100mg orally twice daily for 14 days) or
tetracycline (500mg orally four times daily for 14 days) are acceptable
alternative regimens. For non-pregnant, penicillin-allergic patients pre-
senting with late latent syphilis or latent syphilis of unknown duration,
doxycycline 100mg orally twice daily or tetracycline 500mg orally four
times daily, either to be given for 28 days, are acceptable alternative
therapies, in conjunction with close serologic and clinical follow-up. An
important caveat to the use of these alternative therapies is that the
efficacy of these regimens in HIV-infected patients has not been stud-
ied and should be used with caution. Pregnant patients who are aller-
gic to penicillin should be desensitized and treated with penicillin.
Follow-up should include serial quantitative nontreponemal serologic
tests repeated at six, 12, and 24 months. Persons with HIV should be
monitored more frequently (six, 12, 18, and 24 months after therapy).
Patients who fail to respond (i.e., titers increase four-fold, or an initial-
ly high titer of = 1:32 fails to decline at least fourfold within 12-24
months of therapy, or signs/symptoms consistent with syphilis develop)
and whose CSF analysis to rule out unrecognized CNS infection is nor-
mal, should be re-treated for latent syphilis. Patients with HIV infection
or patients who fail to respond should be managed in consultation with
an infectious diseases specialist.
Public Health Considerations
Key public health strategies that will help prevent and control the trans-
mission of syphilis, HIV, and other STDs in correctional settings include
educating inmates about STDs and routine screening for STDs. Most
public health departments require reporting of some types of STDs;
make sure your correctional facility complies with the reporting rules of
your local and state health departments. Partner notification with eval-
uation, treatment, and follow-up are also essential to limiting the trans-
mission of syphilis and other sexually transmitted infections. The time
frames for partner notification for primary, secondary, and early latent
syphilis are three, six, and 12 months, respectively, before the devel-
opment of symptoms in the index case. All sexual contacts of patients
with late latent syphilis should be evaluated.8
Conclusion
Incarcerated persons are at high risk for STDs. Even the most astute
clinician may find it challenging to correctly diagnose genital ulcer dis-
ease based on medical history and physical examination alone.
Appropriate serologic and microbiologic tests should always be per-
formed to determine whether the cause of GUD is infectious and to
improve diagnostic accuracy. A thorough work-up of genital ulcer dis-
ease should always include HIV screening. Once the diagnosis has
been determined it is important to begin treatment promptly and to
schedule the patient for follow-up. This will prevent sexual transmis-
sion and late sequelae, and ensure an adequate response to therapy.
In the event of treatment failure, HIV status should be re-evaluated.
*DISCLOSURES: Nothing to disclose.
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The United States Conference on
AIDS
Sponsored by the National Minority
AIDS Council
September 18-21, 2003
New Orleans, Louisiana
Call: 202-483-6622
Visit: www.nmac.org
HIV Minifellowship for
Correctional Health Care
Providers
Sponsored by the Univ. of Texas
Medical Branch 
and HEPP Report, Brown Univ.
September 22-24, 2003
Providence, Rhode Island
Call: 409-747-8769
Email: pwelsh@utmb.edu
National Conference on
Correctional Health Care 
October 4-8, 2003
Austin, Texas
Call: 773-880-1460
Visit: www.ncchc.org
Society of Correctional
Physicians (SCP): 
10th Annual Conference 
October 5, 2003
Austin, Texas
Conference fee: 
$50 member/$100 non-member
Call: 800-229-7380
Visit: www.corrdocs.org
41st Annual Meeting of
Infectious Disease Society of
America (IDSA)
October 9-12, 2003
San Diego, California
Call: 703-299-0200
Email: info@idsociety.org
Visit: www.idsociety.org
Management of HIV/AIDS in the
Correctional Setting:
A Live Satellite Videoconference
Sexually Transmitted Diseases &
the HIV Connection
October 21, 2003
12:30-3:30 p.m. EST
CME credits available
Call: 518-262-4674
Email: ybarraj@mail.amc.edu 
Visit: www.amc.edu/patient/hiv/
hivconf/index.htm
4th Annual Centerforce Summit
October 20-22, 2003
Millbrae, California 
Clinician Pre-summit: 
October 18-19, 2003
Call: 415-456-9980 x124
Email: bhoughton@centerforce.org
Visit: www.RDLent.com 
Save the 
Dates
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FDA Approves Gilead's Once-Daily NRTI,
Emtriva
The U.S. Food and Drug Administration (FDA) has
approved Gilead Sciences' once-daily nucleoside
reverse transcriptase inhibitor (NRTI), Emtriva
(emtricitabine), to be used in combination with
other antiretroviral medications to treat HIV.
Emtriva works by blocking an enzyme necessary
for HIV replication. Gilead gained approval for its
other once-daily NRTI, Viread (tenofovir), and is
developing a combination pill containing both
drugs, which it hopes will be available in 2005. The
U.S. wholesaler acquisition cost for Emtriva is
$252.83 for 30 capsules (one month of therapy).
Emtriva is available in pharmacies now. Reuters,
7/2/03
CDC: Doctors Should Not Use Two-Month
Rifampin/Pyrazinamide Regimen for LTBI
The two-month combination therapy using rifampin
and pyrazinamide to treat latent TB infection (LTBI)
can cause severe liver damage and death, and
should not be used, according to a study from the
Centers for Disease Control and Prevention
(CDC). In data collected from January 2000 to
June 2002, the CDC received reports of 48
patients with LTBI who experienced severe liver
injury after receiving the two-drug treatment.
Eleven patients died. The CDC recommends using
a nine-month regimen of isoniazid as the preferred
treatment. The rifampin/pyrazinamide regimen
should be used only if the potential benefits out-
weigh the risk for severe liver injury and death
associated with it. CDC MMWR 2003;52;(31):735-
739.
DHHS Releases Revised ARV Guidelines;
Hopes to Make Drug Selection Easier
The U.S. Department of Health and Human
Services (DHHS) has released an updated version
of the Guidelines for the Use of Antiretroviral
Agents in HIV-Infected Adults and Adolescents.
The new version, which contains a list of suggest-
ed combination regimens for the initiation of anti-
retroviral therapy, is expected to make the selec-
tion of appropriate treatment easier. Based on the
results of clinical trials and expert opinion, the sug-
g sted regimens are classified as "preferred" or
"alternative." The guidelines are available at
ww.aidsinfo.nih.gov, or can be ordered by calling
1-800-448-0440. National Institutes of Health
P ess Release, 7/14/03
Lamivudine + Abacavir + Tenofovir Arm of
S udy Halted Due to Early Virologic Non-
Response
GlaxoSmithKline has notified health care providers
of a high rate of early virologic non-response in
clinical study ESS30009, which was studying ther-
apy-naïve adults receiving once-daily combination
therapy with lamivudine (3TC), abacavir (ABC),
and tenofovir (TDF). Based on the results, the
company recommends that 3TC, ABC, and TDF
not be used as sole therapy for HIV; that any
patients taking this combination be closely moni-
tored and considered for modification of the thera-
py; and that any use of the combination with other
a tiretroviral agents be closely monitored for signs
of treatment failure. AEGiS news service, 7/25/03
N w Guidelines Available for HIV Drug
Resistance Testing
New guidelines on the use of resistance testing
have been published by the American arm of the
International AIDS Society (IAS-USA). The guide-
lines were created by an international panel of
researchers convened in 2002, and includes infor-
mation on how HIV develops resistance to different
HIV drugs; highlights the importance of key muta-
tions; discusses the different types of resistance
tests available; and makes recommendations for
their use in pregnancy and other situations. The
guidelines were initially published in the July 1,
2003 issue of Clinical Infectious Diseases, and are
also available for download on the IAS-USA web-
site, www.iasusa.org. AEGiS news service,
7/21/03
Inside News
Resources
Serving Women in the Correctional System
Through Ryan White CARE Act Programs
www.aids-alliance.org
A resource for CARE Act grantees who serve
women living with HIV/AIDS who are incarcerated
and transitioning back to the community, or newly
released. Includes tips to help grantees get start-
ed, offers examples of other programs across the
country, and directs interested grantees to
resources for more information. 
Body Pro CME/CE
www.thebodypro.com/cme/
A new way to earn CME or CE credits online.
Three-Five Day Hands-on HIV Training
Opportunities for NY and NJ providers
Supported via the New York/New Jersey AIDS
Education & Training Center
**Limited to New York State (NYS) & New Jersey
clinical providers only**
NY Training Locations: Albany, New York City,
Syracuse, Rochester and
Buffalo. To obtain application information call (518)
262-6864 or email: corlewc@mail.amc.edu
Hepatitis C Informational Brochure
www.harmreduction.org
The 32-page informational brochure is geared
toward drug users, and provides information about
HCV infection risks, prevention, screening, and
diagnosis. Copies are available as a free PDF file
or for 35 cents per printed pamphlet. Call (212)
213-6376 x10 for more information. 
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Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through February 28,2004. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. The syphilis rate among the general population in the U.S. in
2001 was:
(a) 22.0 cases per 100,000
(b) 2.2 cases per 100,000
(c) .20 cases per 100,000
(d) None of the above
2. Which of the following groups has had the largest increase in
syphilis rates in the U.S. over the past few years?
(a) Women
(b) Heterosexual men
(c) Men who have sex with men (MSM)
(d) African-American women
3. Recently, the rates of gonorrhea and chlamydia in the U.S.
have:
(a) Remained steady
(b) Decreased
(c) Increased
4. When genital lesions due to HSV are present, the risk for
transmission of HIV is estimated to be:
(a) Reduced by 50%
(b) Two to four times higher 
(c) Twenty times higher
5. Key public health strategies that are essential to preventing
and controlling the transmission of syphilis, HIV, and other STDs
include:
(a) Partner notification
(b) Routine screening for STDs 
(c) Educating patients about STDs and how to prevent them
(d) All of the above
BROWN MEDICAL SCHOOL •  OFFICE OF CONTINUING MEDICAL EDUCATION •  BOX G-A2  •  PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME)to provide continuing medical 
education activities for physicians.  
The use of the Brown Medical School name implies review of the educational format and material only.  The opinions, recommendations 
and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the 
Brown Medical School.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or 
register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
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HEPP Report Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1      
Inside News 5  4  3  2  1   5  4  3  2  1
Save the 
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP Report helps you in your work?
Why or why not?
3. What future topics should HEPP Report address?
4. How can HEPPReport be made more useful to you?
5. Do you have specific comments on this issue?
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